Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026. On December 30, ...

If you are wondering whether Johnson & Johnson shares still offer solid value after a strong run, this article will walk ...

Recent chatter on X about Johnson & Johnson (JNJ) has been buzzing with reactions to the company's latest earnings report and raised 2024 guidance. Posts highlight a notable 6% stock price increase ...

The average one-year price target for Johnson & Johnson (NYSE:JNJ) has been revised to $204.02 / share. This is an increase of 10.96% from the prior estimate of $183.86 dated September 27, 2025. The ...

This company boasts a strong history of dividend growth, making it attractive for income-focused investors. Currently, the stock appears slightly undervalued, but a clear catalyst is needed for it to ...

J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter ...

On July 16, Johnson & Johnson did what I've been waiting for, namely, its revenue and EPS beat Wall Street analysts' expectations by a wide margin. The 42.7% year-over-year decline in sales of its ...